Latest Asbestos Liabilities News

James Hardie Industries saw a 25% sales increase in FY26 driven by the AZEK acquisition but reported a 75% net income decline amid acquisition costs and margin pressures. The company expects synergy gains and adjusted EBITDA growth in FY27.

James Hardie Industries reports a 34% jump in Q2 FY26 net sales driven by the AZEK acquisition and European growth, while grappling with margin pressures and integration costs.

KPMG's latest actuarial report reveals a slight increase in asbestos-related disease liabilities for former James Hardie entities, driven by a notable rise in mesothelioma claims and evolving actuarial assumptions.